



Editor-in-Chief
Feyyaz ONUR, Prof. Dr.
Ankara University, Ankara, Turkey,
E-mail: onur@pharmacy.ankara.edu.tr
ORCID ID: orcid.org/0000-0001-9172-1126

Vice Editor

Gülgün KILCIGİL, Prof. Dr.

Ankara University, Ankara, Turkey E-mail: Gulgun.A.Kılcıgıl@pharmacy.ankara.edu.tr ORCID ID: orcid.org/0000-0001-5626-6922

Associate Editors

Rob VERPOORTE, Prof. Dr. Leiden University, Leiden, Netherlands

Luciano SASO, Prof. Dr. Sapienze University of Rome, Rome, Italy

Fernanda BORGES, Prof. Dr. Porto University, Porto, Portugal

Bezhan CHANKVETADZE, Prof. Dr.

Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia

Ahmet BAŞARAN, Prof. Dr. Hacettepe University, Ankara, Turkey

Tayfun UZBAY, Prof. Dr. Üsküdar University, İstanbul, Turkey Ülkü ÜNDEĞER-BUCURGAT. Prof. Dr.

Hacettepe University, Ankara, Turkey ORCID ID: orcid.org/0000-0002-6692-0366

Müge KILIÇARSLAN, Assoc. Prof. Dr.

Ankara University, Ankara, Turkey ORCID ID: orcid.org/0000-0003-3710-7445

lpek SUNTAR, Assoc. Prof. Dr.

Gazi University, Ankara, Turkey ORCID ID: orcid.org/0000-0001-5626-6922

Advisory Board

Ali H. MERİÇLİ, Prof. Dr., Near East University, Nicosia, Turkish Republic of Northern Cyprus

Berrin ÖZÇELİK, Prof. Dr., Gazi University, Ankara, Turkey

Betül DORTUNÇ, Prof. Dr., Marmara University, İstanbul, Turkey

Christine LAFFORGUE, Prof. Dr., Paris-Sud University, Paris, France

Cihat ŞAFAK, Prof. Dr., Hacettepe University, Ankara, Turkey

Filiz ÖNER, Prof. Dr., Hacettepe University, Ankara, Turkey

Gülten ÖTÜK, Prof. Dr., İstanbul University, İstanbul, Turkey

Hermann BOLT, Prof. Dr., Dortmund University Leibniz Research Centre, Dortmund, Germany

Hildebert WAGNER, Prof. Dr., Ludwig-Maximilians University, Munich, Germany

Jean-Alain FEHRENTZ, Prof. Dr., Montpellier University, Montpellier, France

Joerg KREUTER, Prof. Dr., Johann Wolfgang Goethe University, Frankfurt, Germany

Makbule AŞIKOĞLU, Prof. Dr., Ege University, İzmir, Turkey

Meral KEYER UYSAL, Prof. Dr., Marmara University, İstanbul, Turkey

Meral TORUN, Prof. Dr., Gazi University, Ankara, Turkey

Mümtaz İŞCAN, Prof. Dr., Ankara University, Ankara, Turkey

Robert RAPOPORT, Prof. Dr., Cincinati University, Cincinati, USA

Sema BURGAZ, Prof. Dr., Gazi University, Ankara, Turkey

Wolfgang SADEE, Prof. Dr., Ohio State University, Ohio, USA

Yasemin YAZAN, Prof. Dr., Anadolu University, Eskişehir, Turkey

Yusuf ÖZTÜRK, Prof. Dr., Anadolu University, Eskişehir, Turkey

Yücel KADIOĞLU, Prof. Dr., Atatürk University, Erzurum, Turkey

Zühre ŞENTÜRK, Prof. Dr., Yüzüncü Yıl University, Van, Turkey

TURKISH

JOURNAL OF PHARMACEUTICAL SCIENCES

AIMS AND SCOPE

The Turkish Journal of Pharmaceutical Sciences is the only scientific periodical publication of the Turkish Pharmacists' Association and has been published since April 2004.

Turkish Journal of Pharmaceutical Sciences is an independent international open access periodical journal based on doubleblind peer-review principles. The journal is regularly published 3 times a year. The issuing body of the journal is Galenos Yayinevi/Publishing House.

The aim of Turkish Journal of Pharmaceutical Sciences is to publish original research papers of the highest scientific and clinical value at an international level.

The target audience includes specialists and physicians in all fields of pharmaceutical sciences.

The editorial policies are based on the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2016, archived at http://www.icmje.org/) rules.

ABSTRACTED/INDEXED IN

Web of Science-Emerging Sources Citation Index (ESCI) SCOPUS SJR

Chemical Abstracts Service (CAS)

EBSCO

EMBASE

Analytical Abstracts

International Pharmaceutical Abstracts (IPA)

Medicinal & Aromatic Plants Abstracts (MAPA)

TÜBİTAK/ULAKBİM TR Dizin

Türkiye Atıf Dizini

OPEN ACCESS POLICY

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Open Access Policy is based on the rules of the Budapest Open Access Initiative (BOAI) http://www.budapestopenaccessinitiative.org/. By "open access" to peer-reviewed research literature, we mean its free availability on the public internet, permitting any users to read, download,

copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

CORRESPONDENCE ADDRESS

Editor-in-Chief, Feyyaz ONUR, Prof.Dr.

Address: Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06100 Tandoğan-Ankara, TURKEY E-mail: onur@pharmacy.ankara.edu.tr

PERMISSION

Requests for permission to reproduce published material should be sent to the editorial office. Editor-in-Chief, Prof. Dr. Feyyaz ONUR

ISSUING BODY CORRESPONDING ADDRESS

Issuing Body: Galenos Yavınevi

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1, 34093

İstanbul, TURKEY

Phone: +90 212 621 99 25 Fax: +90 212 621 99 27

E-mail: info@galenos.com.tr

INSTRUCTIONS FOR AUTHORS

Instructions for authors are published in the journal and on the website http://turkjps.org

MATERIAL DISCLAIMER

The author(s) is (are) responsible for the articles published in the JOURNAL.

The editor, editorial board and publisher do not accept any responsibility for the articles.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



Publisher Erkan Mor

Publication Director Nesrin Colak

Web Coordinators Eren Arsel Soner Yıldırım Turgay Akpınar

Graphics Department Ayda Alaca Çiğdem Birinci Project Coordinators Ebru Boz Eda Kolukisa

Hatice Balta Lütfiye Ayhan İrtem Melis Kuru Zeynep Altındağ

Research&Development Büsrah Toparslan

Finance Coordinator Sevinç Çakmak **Publisher Contact**

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1 34093 İstanbul, Turkey

Phone: +90 (212) 621 99 25 Fax: +90 (212) 621 99 27

E-mail: info@galenos.com.tr/yayin@galenos.com.tr

Web: www.galenos.com.tr

Printing at: Özgün Ofset Ticaret Ltd. Şti.

Yeşilce Mah. Aytekin Sk. No: 21 34418 4. Levent, İstanbul, Turkey

Phone: +90 (212) 280 00 09 Printing date: July 2017 ISSN: 1304-530X E-ISSN: 2148-6247

INSTRUCTIONS TO AUTHORS

Turkish Journal of Pharmaceutical Sciences is the official double peerreviewed publication of The Turkish Pharmacists' Association. This journal is published every 4 months (3 issues per year; April, August, December) and publishes the following articles:

- Research articles
- Reviews (only upon the request or consent of the Editorial Board)
- Preliminary results/Short communications/Technical notes/Letters to the Editor in every field or pharmaceutical sciences.

The publication language of the journal is English.

The Turkish Journal of Pharmaceutical Sciences does not charge any article submission or processing charges.

A manuscript will be considered only with the understanding that it is an original contribution that has not been published elsewhere.

The Journal should be abbreviated as "Turk J Pharm Sci" when referenced.

The scientific and ethical liability of the manuscripts belongs to the authors and the copyright of the manuscripts belongs to the Journal. Authors are responsible for the contents of the manuscript and accuracy of the references. All manuscripts submitted for publication must be accompanied by the Copyright Transfer Form [copyright transfer]. Once this form, signed by all the authors, has been submitted, it is understood that neither the manuscript nor the data it contains have been submitted elsewhere or previously published and authors declare the statement of scientific contributions and responsibilities of all authors.

Experimental, clinical and drug studies requiring approval by an ethics committee must be submitted to the JOURNAL with an ethics committee approval report including approval number confirming that the study was conducted in accordance with international agreements and the Declaration of Helsinki (revised 2013) (http://www.wma.net/en/30publications/10policies/b3/). The approval of the ethics committee and the fact that informed consent was given by the patients should be indicated in the Materials and Methods section. In experimental animal studies, the authors should indicate that the procedures followed were in accordance with animal rights as per the Guide for the Care and Use of Laboratory Animals (http://oacu.od.nih.gov/regs/guide/guide.pdf) and they should obtain animal ethics committee approval.

Authors must provide disclosure/acknowledgment of financial or material support, if any was received, for the current study.

If the article includes any direct or indirect commercial links or if any institution provided material support to the study, authors must state in the cover letter that they have no relationship with the commercial product, drug, pharmaceutical company, etc. concerned; or specify the type of relationship (consultant, other agreements), if any.

Authors must provide a statement on the absence of conflicts of interest among the authors and provide authorship contributions.

All manuscripts submitted to the journal are screened for plagiarism using the 'iThenticate' software. Results indicating plagiarism may result in manuscripts being returned or rejected.

The Review Process

This is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass initial evaluation are sent for external peer review, and the Editor-in-Chief assigns an Associate Editor. The Associate Editor sends the manuscript to at least two reviewers (internal and/or external reviewers). The reviewers must review the manuscript within 21 days. The Associate Editor recommends a decision based on the reviewers' recommendations and returns the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.

The scientific board guiding the selection of the papers to be published in the Journal consists of elected experts of the Journal and if necessary, selected from national and international authorities. The Editor-in-Chief, Associate Editors may make minor corrections to accepted manuscripts that do not change the main text of the paper.

In case of any suspicion or claim regarding scientific shortcomings or ethical infringement, the Journal reserves the right to submit the manuscript to the supporting institutions or other authorities for investigation. The Journal accepts the responsibility of initiating action but does not undertake any responsibility for an actual investigation or any power of decision.

The Editorial Policies and General Guidelines for manuscript preparation specified below are based on "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2016, archived at http://www.icmje.org/).

Preparation of research articles, systematic reviews and meta-analyses must comply with study design guidelines:

CONSORT statement for randomized controlled trials (Moher D, Schultz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285: 1987-91) (http://www.consortstatement.org/);

PRISMA statement of preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(7): e1000097.) (http://www.prisma-statement.org/);

STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al., for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-4.) (http://www.stard-statement.org/);

STROBE statement, a checklist of items that should be included in reports of observational studies (http://www.strobe-statement.org/);

MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12).

GENERAL GUIDELINES

Manuscripts can only be submitted electronically through the Journal Agent website (http://journalagent.com/tjps/) after creating an account. This system allows online submission and review.

TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKISH | TURKIS

INSTRUCTIONS TO AUTHORS

The manuscripts are archived according to ICMJE, Web of Science-Emerging Sources Citation Index (ESCI), SCOPUS, Chemical Abstracts, EBSCO, EMBASE, Analytical Abstracts, International Pharmaceutical Abstracts, MAPA(Medicinal & Aromatic Plants Abstracts), Tübitak/Ulakbim Turkish Medical Database, Türkiye Citation Index Rules.

Format: Manuscripts should be prepared using Microsoft Word, size A4 with 2.5 cm margins on all sides, 12 pt Arial font and 1.5 line spacing.

Abbreviations: Abbreviations should be defined at first mention and used consistently thereafter. Internationally accepted abbreviations should be used; refer to scientific writing guides as necessary.

Cover letter: The cover letter should include statements about manuscript type, single-Journal submission affirmation, conflict of interest statement, sources of outside funding, equipment (if applicable), for original research articles.

REFERENCES

Authors are solely responsible for the accuracy of all references.

In-text citations: References should be indicated as a superscript immediately after the period/full stop of the relevant sentence. If the author(s) of a reference is/are indicated at the beginning of the sentence, this reference should be written as a superscript immediately after the author's name. If relevant research has been conducted in Turkey or by Turkish investigators, these studies should be given priority while citing the literature.

Presentations presented in congresses, unpublished manuscripts, theses, Internet addresses, and personal interviews or experiences should not be indicated as references. If such references are used, they should be indicated in parentheses at the end of the relevant sentence in the text, without reference number and written in full, in order to clarify their nature.

References section: References should be numbered consecutively in the order in which they are first mentioned in the text. All authors should be listed regardless of number. The titles of Journals should be abbreviated according to the style used in the Index Medicus.

Reference Format

Journal: Last name(s) of the author(s) and initials, article title, publication title and its original abbreviation, publication date, volume, the inclusive page numbers. Example: Collin JR, Rathbun JE. Involutional entropion: a review with evaluation of a procedure. Arch Ophthalmol. 1978;96:1058-1064

Book: Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the extract cited.

Example: Herbert L. The Infectious Diseases (1st ed). Philadelphia; Mosby Harcourt; 1999:11;1-8.

Book Chapter: Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece.

Example: O'Brien TP, Green WR. Periocular Infections. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases (4th ed). Philadelphia; W.B. Saunders Company;1998:1273-1278.

Books in which the editor and author are the same person: Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition,

place of publication, date of publication and inclusive page numbers of the cited piece. Example: Solcia E, Capella C, Kloppel G. Tumors of the exocrine pancreas. In: Solcia E, Capella C, Kloppel G, eds. Tumors of the Pancreas. 2nd ed. Washington: Armed Forces Institute of Pathology; 1997:145-210.

TABLES, GRAPHICS, FIGURES, AND IMAGES

All visual materials together with their legends should be located on separate pages that follow the main text.

Images: Images (pictures) should be numbered and include a brief title. Permission to reproduce pictures that were published elsewhere must be included. All pictures should be of the highest quality possible, in

JPEG format, and at a minimum resolution of 300 dpi.

Tables, Graphics, Figures: All tables, graphics or figures should be enumerated according to their sequence within the text and a brief descriptive caption should be written. Any abbreviations used should be defined in the accompanying legend. Tables in particular should be explanatory and facilitate readers' understanding of the manuscript, and should not repeat data presented in the main text.

MANUSCRIPT TYPES

Original Articles

Clinical research should comprise clinical observation, new techniques or laboratories studies. Original research articles should include title, structured abstract, key words relevant to the content of the article, introduction, materials and methods, results, discussion, study limitations, conclusion references, tables/figures/images and acknowledgement sections. Title, abstract and key words should be written in both Turkish and English. The manuscript should be formatted in accordance with the above-mentioned guidelines and should not exceed 16 A4 pages.

Title Page: This page should include the title of the manuscript, short title, name(s) of the authors and author information. The following descriptions should be stated in the given order:

- 1. Title of the manuscript (Turkish and English), as concise and explanatory as possible, including no abbreviations, up to 135 characters
- 2. Short title (Turkish and English), up to 60 characters
- 3. Name(s) and surname(s) of the author(s) (without abbreviations and academic titles) and affiliations
- 4. Name, address, e-mail, phone and fax number of the corresponding author.
- 5. The place and date of scientific meeting in which the manuscript was presented and its abstract published in the abstract book, if applicable

Abstract: A summary of the manuscript should be written in both Turkish and English. References should not be cited in the abstract. Use of abbreviations should be avoided as much as possible; if any abbreviations are used, they must be taken into consideration independently of the abbreviations used in the text. For original articles, the structured abstract should include the following sub-headings:

Objectives: The aim of the study should be clearly stated.

Materials and Methods: The study and standard criteria used should be defined; it should also be indicated whether the study is randomized or not, whether it is retrospective or prospective, and the statistical methods applied should be indicated, if applicable.

INSTRUCTIONS TO AUTHORS

Results: The detailed results of the study should be given and the statistical significance level should be indicated.

Conclusion: Should summarize the results of the study, the clinical applicability of the results should be defined, and the favorable and unfavorable aspects should be declared.

Keywords: A list of minimum 3, but no more than 5 key words must follow the abstract. Key words in English should be consistent with "Medical Subject Headings (MESH)" (www.nlm.nih.gov/mesh/MBrowser.html). Turkish key words should be direct translations of the terms in MESH.

Original research articles should have the following sections:

Introduction: Should consist of a brief explanation of the topic and indicate the objective of the study, supported by information from the literature.

Materials and Methods: The study plan should be clearly described, indicating whether the study is randomized or not, whether it is retrospective or prospective, the number of trials, the characteristics, and the statistical methods used.

Results: The results of the study should be stated, with tables/figures given in numerical order; the results should be evaluated according to the statistical analysis methods applied. See General Guidelines for details about the preparation of visual material.

Discussion: The study results should be discussed in terms of their favorable and unfavorable aspects and they should be compared with the literature. The conclusion of the study should be highlighted.

Study Limitations: Limitations of the study should be discussed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

Conclusion: The conclusion of the study should be highlighted.

Acknowledgements: Any technical or financial support or editorial

contributions (statistical analysis, English/Turkish evaluation) towards the study should appear at the end of the article.

References: Authors are responsible for the accuracy of the references. See General Guidelines for details about the usage and formatting required.

Review Articles

Review articles can address any aspect of clinical or laboratory pharmaceuticals. Review articles must provide critical analyses of contemporary evidence and provide directions of or future research. Most review articles are commissioned, but other review submissions are also welcome. Before sending a review, discussion with the editor is recommended.

Reviews articles analyze topics in depth, independently and objectively. The first chapter should include the title in Turkish and English, an unstructured summary and key words. Source of all citations should be indicated. The entire text should not exceed 25 pages (A4, formatted as specified above).

CORRESPONDENCE

All correspondence should be directed to the Turkish Journal of Pharmaceutical Sciences editorial board:

Post: Turkish Pharmacists' Association

Address: Willy Brandt Sok. No: 9 06690 Ankara, TURKEY

Phone: +90 312 409 8136 Fax: +90 312 409 8132

Web Page: http://turkjps.org/home/ E-mail: onur@pharmacy.ankara.edu.tr

CONTENTS

Original Articles

95 Assessment of Cytotoxicity Profiles of Different Phytochemicals: Comparison of Neutral Red and MTT Assays in Different Cells in Different Time Periods

Fenoliklerin Sitotoksisite Profillerinin Değerlendirilmesi: Farklı Hücrelerde Farklı Zaman Aralıklarında Nötral Kırmızı ve MTT Yöntemlerinin Karşılaştırılması

Merve BACANLI, Hatice Gül ANLAR, A. Ahmet BAŞARAN, Nurşen BAŞARAN

108 Self-Emulsifying Formulation of Indomethacin with Improved Dissolution and Oral Absorption

İndomethacinin Geliştirilmiş Çözünürlük ve Sözlü İzolasyon ile Formülasyonunun Özel Emülsifilleştirilmesi Subhash Chandra Bose PENJURI, Saritha DAMINENI, Nagaraju RAVOURU, Srikanth Reddy POREDDY

120 Development, Internal and External Validation of Naproxen Sodium Sustained Release Formulation: an Level A In Vitro-In Vivo Correlation

Naproksen Sodyum Süreli Serbest Formülasyonun Geliştirilmesi, İç ve Dış Olarak Doğrulaması: Bir Düzey A İn Vitro-İn Vivo Korelasyon Ramesh NARAYANASAMY, Ramakrishna SHABARAYA

127 Subcutaneous Toxicity of Agmatine in Rats

Sıçanlarda Subkütan Agmatin Toksisitesi Tayfun UZBAY, Fatma Duygu KAYA YERTUTANOL, Ahmet MİDİ, Burcu ÇEVRELİ

134 Comparative Anatomical Studies on Three Endemic Ononis L. (Leguminosae) Species Growing in Turkey

Türkiye'de Yetişen Üç Endemik Ononis L. (Leguminosae) Türü Üzerinde Karşılaştırmalı Anatomik Çalışmalar Ayşe BALDEMİR, Maksut COŞKUN

141 Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers

Endometrial ve Ovaryum Kanserinde Tanısal Değer Yönünden Serum Biyobelirteci Olarak Vitronektin, Solubl Epitel-Kaderin ve TGF-β1'in Değerlendirilmesi

Taylan TURAN, Meral TORUN, Funda ATALAY, Aymelek GÖNENÇ

148 Desloratadine-Eudragit® RS100 Nanoparticles: Formulation and Characterization

Desloratidin-Euragit® RS100 Nanopartikülleri: Formülasyon ve Karakterizasyon Evrim YENİLMEZ

157 Antibacterial, Antitubercular and Antiviral Activity Evaluations of Some Arylidenehydrazide Derivatives Bearing Imidazo[2,1-b]thiazole Moiety

İmidazo[2,1-b]tiyazol Çekirdeği Taşıyan Bazı Arilidenhidrazit Türevlerinin Antibakteriyel, Antitüberküler ve Antiviral Aktivite Tayinleri Nuray ULUSOY GÜZELDEMİRCİ, Berin KARAMAN, Ömer KÜÇÜKBASMACI

164 Activation of Two Different Drugs Used in Alzheimer's Disease Treatment on Human Carbonic Anhydrase Isozymes I and II Activity: an *In Vitro* Study

Alzheimer Hastalığının Tedavisinde Kullanılan İki Farklı İlacın İnsan Karbonik Anhidraz I ve II İzoenzim Aktiviteleri Üzerindeki Aktivasyonu: İn Vitro Çalışma Esra DİLEK

169 In Vitro Evaluation of the Toxicity of Cobalt Ferrite Nanoparticles in Kidney Cell

Kobalt Ferrit Nanopartiküllerinin Böbrek Hücresi Üzerine Güvenliğinin İn Vitro Değerlendirmesi Mahmoud ABUDAYYAK, Tuba ALTINÇEKİÇ GÜRKAYNAK, Gül ÖZHAN

JOURNAL OF PHARMACEUTICAL SCIENCES

CONTENTS

174 Synthesis and Antioxidant Properties of New Oxazole-5(4H)-one Derivatives

Yeni Oksazol-5(4H)-one Türevlerinin Sentez ve Antioksidan Özellikleri Canan KUŞ, Ezgi UĞURLU, Elçin D. ÖZDAMAR, Benay CAN-EKE

179 Evaluation of Antioxidant Activities and Phenolic Compounds of *Scorzonera latifolia* (Fisch. & Mey.) DC. Collected from Different Geographic Origins in Turkey

Türkiye'nin Farklı Coğrafik Bölgelerinden Toplanmış Scorzonera latifolia (Fisch. & Mey.) DC. Örneklerinin Fenolik Bileşiklerinin ve Antioksidan Aktivitelerinin Değerlendirilmesi

Özlem Bahadır AÇIKARA, Burçin ERGENE ÖZ, Filiz BAKAR, Gülçin SALTAN ÇİTOĞLU, Serpil NEBİOĞLU

185 Assessment of Genotoxic Effects of Pendimethalin in Chinese Hamster Over Cells by the Single Cell Gel Electrophoresis (Comet) Assay

Pendimetalinin Genotoksik Etkilerinin Çin Hamster Over Hücrelerinde Tek Hücre Jel Elektroforez (Comet) Yöntemiyle Değerlendirilmesi

Nazlı DEMİR, Sevtap AYDIN, Ülkü ÜNDEĞER BUCURGAT

191 Ocular Application of Dirithromycin Incorporated Polymeric Nanoparticles: an In Vitro Evaluation

Diritromisin Yüklü Polimerik Nanopartiküllerin Oküler Uygulanması: İn Vitro Değerlendirme Ebru BAŞARAN

Review articles

201 Pharmacological and Toxicological Properties of Eugenol

Öjenolün Farmakolojik ve Toksikolojik Özellikleri Solmaz MOHAMMADI NEJAD, Hilal ÖZGÜNEŞ, Nurşen BAŞARAN

207 Contribution of Rho-kinase and Adenosine Monophosphate-Activated Protein Kinase Signaling Pathways to Endothelium-Derived Contracting Factors Responses

Endotel Kaynaklı Kastırıcı Faktör Yanıtlarına Rho-kinaz ve Adenosin Monofosfatla Aktive Edilmiş Protein Kinaz Sinyal Yolaklarının Katkısı

Cennet BALCILAR, Işıl ÖZAKCA, Vecdi Melih ALTAN

Volume: 14, No: 2, Year: 2017

CONTENTS

Original articles

Assessment of Cytotoxicity Profiles of Different Phytochemicals: Comparison of Neutral Red and MTT Assays Different Cells in Different Time Periods	in
Merve BACANLI, Hatice Gül ANLAR, A. Ahmet BAŞARAN, Nurşen BAŞARAN	95
Self-Emulsifying Formulation of Indomethacin with Improved Dissolution and Oral Absorption Subhash Chandra Bose PENJURI, Saritha DAMINENI, Nagaraju RAVOURU, Srikanth Reddy POREDDY Development, Internal and External Validation of Naproxen Sodium Sustained Release	108
Formulation: an Level A <i>In Vitro-In Vivo</i> Correlation Ramesh NARAYANASAMY, Ramakrishna SHABARAYA	120
Subcutaneous Toxicity of Agmatine in Rats Tayfun UZBAY, Fatma Duygu KAYA YERTUTANOL, Ahmet MİDİ, Burcu ÇEVRELİ	127
Comparative Anatomical Studies on Three Endemic <i>Ononis</i> L. (<i>Leguminosae</i>) Species Growing in Turkey Ayşe BALDEMİR, Maksut COŞKUN	134
Assessment of Vitronectin, Soluble Epithelial-Cadherin and TGF-β1 as a Serum Biomarker with Predictive Value for Endometrial and Ovarian Cancers	
Taylan TURAN, Meral TORUN, Funda ATALAY, Aymelek GÖNENÇ	141
Desloratadine-Eudragit® RS100 Nanoparticles: Formulation and Characterization Evrim YENİLMEZ	148
Antibacterial, Antitubercular and Antiviral Activity Evaluations of Some Arylidenehydrazide Derivatives Bearing Imidazo[2,1-b]thiazole Moiety Nuray ULUSOY GÜZELDEMİRCİ, Berin KARAMAN, Ömer KÜÇÜKBASMACI	157
Activation of Two Different Drugs Used in Alzheimer's Disease Treatment on Human Carbonic Anhydrase Isozymes I and II Activity: an <i>In Vitro</i> Study	
Esra DİLEK	164
<i>In Vitro</i> Evaluation of the Toxicity of Cobalt Ferrite Nanoparticles in Kidney Cell Mahmoud ABUDAYYAK, Tuba ALTINÇEKİÇ GÜRKAYNAK, Gül ÖZHAN	169
Synthesis and Antioxidant Properties of New Oxazole-5(4H)-one Derivatives	
Canan KUŞ, Ezgi UĞURLU, Elçin D. ÖZDAMAR, Benay CAN-EKE	174
(Fisch. & Mey.) DC. Collected From Different Geographic Origins in Turkey Özlem Bahadır AÇIKARA, Burçin ERGENE ÖZ, Filiz BAKAR, Gülçin SALTAN ÇİTOĞLU, Serpil NEBİOĞLU	179
Assessment of Genotoxic Effects of Pendimethalin in Chinese Hamster Over Cells by the Single Cell Gel Electrophoresis (Comet) Assay	
Nazlı DEMİR, Sevtap AYDIN, ÜİKÜ ÜNDEĞER BUCURGAT	185
Ocular Application of Dirithromycin Incorporated Polymeric Nanoparticles: an <i>In Vitro</i> Evaluation Ebru BAŞARAN	191
Review articles	
Pharmacological and Toxicological Properties of Eugenol Solmaz MOHAMMADI NEJAD, Hilal ÖZGÜNEŞ, Nurşen BAŞARAN	201
Contribution of Rho-kinase and Adenosine Monophosphate-Activated Protein Kinase Signaling Pathways to Endothelium-Derived Contracting Factors Responses	
Cennet BALCILAR, Işıl ÖZAKCA, Vecdi Melih ALTAN	207